Renpeng Zhou
Associate Research ScientistCards
About
Research
Publications
2024
Macrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization
Zhou R, Xue S, Cheng Y, Chen Y, Wang Y, Xing J, Liu H, Xu Y, Lin Y, Pei Z, Wei X, Ding J, Li S, Wang K, Yao F, Zhao Y, Ding C, Hu W. Macrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization. Journal Of Nanobiotechnology 2024, 22: 578. PMID: 39300463, PMCID: PMC11414146, DOI: 10.1186/s12951-024-02822-9.Peer-Reviewed Original ResearchConceptsCollagen-induced arthritisNanotherapeutic systemInflamed jointsRheumatoid arthritisMacrophage polarizationModulating macrophage polarizationDelay disease progressionDebilitating autoimmune diseaseChronic joint inflammationComprehensive in vitroAnti-inflammatory M2 phenotypeReduced synovial inflammationEnhanced cellular uptakeIntra-articular injectionRheumatoid arthritis treatmentPro-inflammatory M1Treatment optionsAutoimmune diseasesRepolarize macrophagesBiomimetic nanoparticlesDisease progressionMouse modelNanoparticlesTherapeutic strategiesSide effectsA Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects
Yao F, Wang C, Ding J, Zhang Q, Zheng L, Zhang Q, Yang T, Zhang X, Shan Y, Hou S, Wang H, Zhou R, Hu W. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects. Drug Design Development And Therapy 2024, 18: 3891-3901. PMID: 39224901, PMCID: PMC11368109, DOI: 10.2147/dddt.s470619.Peer-Reviewed Original ResearchConceptsHealthy Chinese male subjectsChinese male subjectsGeometric mean ratiosAnti-drug antibodiesDouble-blindMale subjectsRates of anti-drug antibodiesPK parametersNon-radiographic axial spondyloarthritisIncidence of TEAEsPhase I studyPrimary study endpointInterleukin (IL)-17AArea under the curveEnthesitis-related arthritisTreatment of psoriasisConfidence intervalsSafety profileSingle doseHidradenitis suppurativaSecukinumabStudy endpointAdverse eventsAxial spondyloarthritisImmunogenicity analysisNS8593 inhibits chondrocyte ferroptosis and alleviates cartilage injury in rat adjuvant arthritis through TRPM7 / HO-1 pathway
Hao W, Zhu R, Zhang H, Chen Y, Li S, Zhou F, Hu W, Zhou R. NS8593 inhibits chondrocyte ferroptosis and alleviates cartilage injury in rat adjuvant arthritis through TRPM7 / HO-1 pathway. The International Journal Of Biochemistry & Cell Biology 2024, 174: 106618. PMID: 39053766, DOI: 10.1016/j.biocel.2024.106618.Peer-Reviewed Original ResearchTransient receptor potential melastatin 7Inhibit TRPM7 channelsHeme oxygenase-1TRPM7 channelsTRPM7 inhibitorRheumatoid arthritisHeme oxygenase-1 pathwayRat adjuvant arthritisExpression of heme oxygenase-1Treatment of RAChondrocyte ferroptosisFerroptosis inducer erastinIn vitro modelCartilage destructionAA ratsNS8593Oxidative stress injuryRestoring redox balanceArticular cartilage damageAdjuvant arthritisPotential novel drugOxygenase-1Restored cell viabilityArticular cartilage destructionReduced cytotoxicityEfferocytosis: Unveiling its potential in autoimmune disease and treatment strategies
Xing J, Wang K, Xu Y, Pei Z, Yu Q, Liu X, Dong Y, Li S, Chen Y, Zhao Y, Yao F, Ding J, Hu W, Zhou R. Efferocytosis: Unveiling its potential in autoimmune disease and treatment strategies. Autoimmunity Reviews 2024, 23: 103578. PMID: 39004157, DOI: 10.1016/j.autrev.2024.103578.Peer-Reviewed Original ResearchClearance of apoptotic cellsApoptotic cellsDegradation of apoptotic cellsPhagocyte surface receptorsAutoimmune diseasesInternalize apoptotic cellsEfficient clearance of apoptotic cellsSelf-antigensRelease of self-antigensSystemic lupus erythematosusTreat autoimmune diseasesSignaling pathwayType 1 diabetesSurface receptorsImmunosuppressive signalsImmune toleranceLupus erythematosusImmune homeostasisTreatment strategiesEfferocytosis processEfficient clearanceInadequate clearanceTherapeutic strategiesImmune responsePhagocytesNS8593 inhibits sodium nitroprusside-induced chondrocyte apoptosis by mediating the STING signaling pathway
Zhu R, Hao W, Li S, Chen Y, Zhou F, Zhou R, Hu W. NS8593 inhibits sodium nitroprusside-induced chondrocyte apoptosis by mediating the STING signaling pathway. Heliyon 2024, 10: e31375. PMID: 38831839, PMCID: PMC11145487, DOI: 10.1016/j.heliyon.2024.e31375.Peer-Reviewed Original ResearchTransient receptor potential cation channel subfamily M member 7STING signaling pathwayCyclic GMP-AMP synthase (cGAS)-stimulatorSNP-induced decreaseAtrial fibrillation therapyPhosphorylation levelsSignaling pathwayApoptosis in vitroCell viabilityNS8593Atrial fibrillationDose-dependentlyImprove atrial fibrillationInterferon genesSNP-induced chondrocyte apoptosisArticular cartilage damageApoptosisChondrocyte apoptosisFeatures of osteoarthritisChondrocyte apoptosis in vitroArticular cartilage destructionCartilage destructionCartilage damageStingsTreatmentSafety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects
Sun C, Liu H, Ouyang Z, Ding J, Zhang Q, Ma H, Xu D, Zhang Q, Zhou R, Yang M, Hu W. Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects. Expert Opinion On Investigational Drugs 2024, 33: 533-542. PMID: 38662639, DOI: 10.1080/13543784.2024.2347302.Peer-Reviewed Original ResearchArea under the curveAscending-dose studyFood effect studyHealthy subjectsPlacebo-controlled phase I studySARS-CoV-2Increased approximately dose-proportionallyPlasma concentrationsTreatment-related adverse eventsApproximately dose-proportionallyPhase I studyHigh-fat mealBroad-spectrum antiviral drugsPreclinical activityDose proportionalityDouble-blindPlacebo-controlledReport safetyDose groupSafety profileStandard mealAdverse eventsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2TRPM7 facilitates fibroblast-like synoviocyte proliferation, metastasis and inflammation through increasing IL-6 stability via the PKCα-HuR axis in rheumatoid arthritis
Lin Y, Chen Y, Hu W, Liu X, Hao W, Xing J, Ding J, Xu Y, Yao F, Zhao Y, Wang K, Li S, Yu Q, Hu W, Zhou R. TRPM7 facilitates fibroblast-like synoviocyte proliferation, metastasis and inflammation through increasing IL-6 stability via the PKCα-HuR axis in rheumatoid arthritis. International Immunopharmacology 2024, 132: 111933. PMID: 38581988, DOI: 10.1016/j.intimp.2024.111933.Peer-Reviewed Original ResearchConceptsTransient receptor potential melastatin 7Rheumatoid arthritisInhibition of transient receptor potential melastatin 7Human RA patientsSynovial hyperplasiaAdjuvant-induced arthritis ratsIncreased TRPM7 expressionIL-6 mRNATreatment of RAPathogenesis of RAFibroblast-like synoviocytesTRPM7 silencingProgression of rheumatoid arthritisTRPM7 expressionChannel inhibitionCation channelsRA patientsMetastasisPharmacological inhibitionArthritis ratsInflammationNuclear translocationSynoviocyte proliferationHyperplasiaProliferationExtracellular CIRP induces abnormal activation of fibroblast-like synoviocytes from patients with RA via the TLR4-mediated HDAC3 pathways
Yao F, Zhao Y, Yu Q, Hu W, Lin Y, Chen Y, Li L, Sun C, Li S, Wang K, Yang M, Zhou R, Hu W. Extracellular CIRP induces abnormal activation of fibroblast-like synoviocytes from patients with RA via the TLR4-mediated HDAC3 pathways. International Immunopharmacology 2024, 128: 111525. PMID: 38218010, DOI: 10.1016/j.intimp.2024.111525.Peer-Reviewed Original ResearchConceptsExtracellular cold-inducible RNA-binding proteinCold-inducible RNA-binding proteinToll-like receptor 4Histone deacetylase 3Endogenous proinflammatory moleculesRheumatoid arthritisActivity of RA-FLSAA ratsAbnormal activationProinflammatory moleculesEffect of cold-inducible RNA-binding proteinHistone deacetylase 3 knockdownRelease of IL-1bSeverity of arthritisFibroblast-like synoviocytesDevelopment of rheumatoid arthritisRA-FLSActivation of fibroblast-like synoviocytesIL-33Expression of N-cadherinProinflammatory effectsArthritis severityIL-1BInflammatory diseasesReceptor 4IUPHAR ECR review: The cGAS-STING pathway: Novel functions beyond innate immune and emerging therapeutic opportunities
He X, Wedn A, Wang J, Gu Y, Liu H, Zhang J, Lin Z, Zhou R, Pang X, Cui Y. IUPHAR ECR review: The cGAS-STING pathway: Novel functions beyond innate immune and emerging therapeutic opportunities. Pharmacological Research 2024, 201: 107063. PMID: 38216006, DOI: 10.1016/j.phrs.2024.107063.Peer-Reviewed Original ResearchStimulator of interferon genesAdaptor protein complex 1Function of STINGRegulation of cellular metabolismRegulatory functionsRegulation of stimulator of interferon genesInnate immune signaling pathwaysImmune signaling pathwaysInnate immune regulationInnate immune sensorsCellular physiologyCGAS-STING pathwayDNA repairNegative regulatorComplex regulationCellular metabolismCytosolic DNAStimulator of interferon genes agonistsCell deathAP-1Stimulators of interferon genes signallingSignaling pathwayMolecular mechanismsImmune regulatory drugImmune sensorsSafety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
Fan Y, Zhang X, Zhang Q, Zheng L, Zhou R, Sun C, Wang X, Song K, He Z, Wang H, Zhang Q, Hu W. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. Clinical Pharmacokinetics 2024, 63: 293-302. PMID: 38198010, DOI: 10.1007/s40262-023-01330-7.Peer-Reviewed Original ResearchP2X3 receptor antagonistAdverse eventsReceptor antagonistHealthy subjectsChronic coughPlacebo-controlled phase 1 trialModerate adverse eventsMost adverse eventsTwice-daily dosingSelective P2X3 receptor antagonistPhase 1 studyPhase 1 trialUnexplained chronic coughSingle oral doseStudy phaseMedian tmaxPrimary endpointGood tolerabilityOral doseTherapeutic optionsResultsA totalDrug exposureMean t1/2Lower incidenceFood intake